**Core Concept**
Eirenz, also known as efavirenz, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV/AIDS. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV.

**Why the Correct Answer is Right**
Efavirenz binds to the reverse transcriptase enzyme, altering its shape and preventing the incorporation of nucleotides into the viral DNA. This leads to a disruption in the viral replication process, ultimately reducing the viral load in the body. The binding of efavirenz to the reverse transcriptase enzyme is non-competitive, meaning it does not compete with the substrate (nucleotides) for binding, but rather alters the enzyme's conformation to prevent substrate binding.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because efavirenz does not act as a protease inhibitor, which is a different class of antiretroviral drugs that targets the protease enzyme responsible for cleaving viral polyproteins.

**Option B:** This option is incorrect because efavirenz does not act as a fusion inhibitor, which is a class of antiretroviral drugs that prevents the fusion of viral and host cell membranes.

**Option C:** This option is incorrect because efavirenz does not act as a nucleoside reverse transcriptase inhibitor (NRTI), which is a class of antiretroviral drugs that incorporates into the viral DNA and acts as a chain terminator.

**Clinical Pearl / High-Yield Fact**
Efavirenz is known to have neuropsychiatric side effects, including dizziness, insomnia, and vivid dreams, which can be severe in some cases. It is essential to monitor patients for these side effects and adjust the dosage or switch to an alternative medication if necessary.

**Correct Answer: C. Efavirenz acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) by inhibiting the reverse transcriptase enzyme, disrupting viral replication.**